An advisory panel for the Food and Drug Administration concluded Wednesday that Switzerland.-based Novartis AG’s version of Amgen’s arthritis drug Enbrel should be approved, according to Reuters. The ...

The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...

European Commission Clears First Enbrel Biosimilar Ahead of US The European Commission over the weekend signed off on the first biosimilar for Amgen’s blockbuster rheumatoid arthritis treatment Enbrel ...

Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District Court ...

A US District Court Judge in New Jersey on Friday upheld the validity of two of Amgen’s patents for its blockbuster arthritis treatment Enbrel (etanercept), preventing the launch of a biosimilar ...

(Reuters) - Novartis AG's cheaper version of Amgen Inc's blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug ...